Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | Breast cancer hormone therapy after menopause; also a fertility drug. | Aromatase inhibitor for breast cancer treatment and prevention. |
| Body system | Cancer | Cancer |
| Drug class | Aromatase inhibitors | Aromatase inhibitors |
| Supply | Prescription onlyWHO essential medicine | Prescription onlyWHO essential medicine |
| Main uses | Hormone-receptor-positive breast cancer after menopause, Ovulation induction in PCOS (off-label) | Breast cancer after menopause, Breast cancer prevention (high risk) |
| How it works | Shuts down oestrogen production after menopause. | Cuts oestrogen levels after menopause. |
| Starts working | — | — |
| Half-life | About 2 days | About 50 hours |
| Typical adult dose | Breast cancer: 2.5 mg once a day for 5–10 years. | 1 mg once a day. |
| Forms | Tablet | Tablet |
| Common side effects | Joint and muscle pain, Hot flushes, Fatigue, Raised cholesterol | Hot flushes, Joint pain, Tiredness |
| Serious side effects | Bone loss and fractures, Heart problems (rare) | Bone thinning, Severe skin reactions (rare) |
| Don't take if | — | — |
| Alcohol | — | — |
| Pregnancy | Usually avoidedContraindicated in pregnancy (fertility use is before conception). | Usually avoidedNot for use in pregnancy. |
| Breastfeeding | — | — |
| In use since | 1996 | 1995 |
| Brand names | United States: FemaraUnited Kingdom: FemaraIndia: Letroz, Femara, Letoval | United States: ArimidexUnited Kingdom: ArimidexIndia: Armotraz, Altraz |
| Legal status | — | — |
| ATC code | L02BG04 | L02BG03 |
Taken together
No interaction between these medicines is recorded in the atlas.
Open in the interaction checker